Noster major conlationem est quod sustinetur, release Lorem integrates ad commoda chemotherapy et immunotherapy, et primum duo sunt simul et applicantur ad intratumor therapy per interveniente. It integrates local and global treatment, and increases the concentration and time of drug action through sustained release of drugs within the tumor, which not only plays a local anticancer effect of chemotherapy drugs, but also takes into account the role of systemic immunotherapy, thus making up for the shortcomings of other therapies, providing new ideas and approaches for cancer treatment, especially for middle and advanced tumors, especially for reducing tumor recurrence Et inhibentes tumore transitus habet ipsum momenti valorem; Umpicum Lorem habet utilitatem usura tumore ut antigen fons et autologus vaccine, quae etiam in linea cum progressionem flecte de personalized medicina. And applied to the clinic, hapten combined with chemotherapy drugs for sustained release treatment of pancreatic cancer primary focus, while inducing distal effect, the essence of which is to induce immune response, T-cell-related CD4, CD8, DC, T and NK cells, and B-cell-related tumor autoantibodies: Antibodies to P53, P16, Cmyc, Zeta, IMP1, Koc, Survivin, P62, HCc1 et aliud oncogenes, hoc est primum invenire quod T et B sunt implicari in immunes responsio, et orci pancreantis in altaque ad interventional curatio ad provectus Cancer Association, in National Medical Research Centre Radiology et Lorem, et National Interventional Medicine innovation Alliance erat published in

Journal de C. Radiology, Volume XLIII, Number XIX, MMXXIV, 1636-1648.